Active Studies

The purpose of this study is to learn if taking a drug called Apixaban after an ablation
procedure keeps blood clots from forming and lowers the chance of having a stroke in
patients with ventricular tachycardia (VT).

This study will compare two different exercise and diet programs for Type 2 diabetic patients with diabetic neuropathy. Half of participants will be assigned at random to receive the diet and exercise counseling, typically provided to patients with diabetes while the other half of participants will receive supervised exercise and activity counseling, together with more intensive diet counseling. The study's primary goal is to compare the change in the number of small nerves that reach to the surface of the skin, as measured by skin biopsy, between the two treatment groups.

This study is a prospective, multicenter, randomized (2:1) controlled study to evaluate the
safety and effectiveness of the LARIAT System to percutaneously isolate and ligate the Left
Atrial Appendage from the left atrium as an adjunct to planned pulmonary vein isolation
(PVI) catheter ablation in the treatment of subjects with symptomatic persistent or
longstanding persistent atrial fibrillation.

This study will be conducted in two stages:

- Limited Early Stage (Stage 1): up to 175 subjects at up to 15 sites

- Pivotal Stage (Stage 2): up to 600 subjects at up to 50 sites All patients from both
stages will be included in the primary analysis.

The purpose of this study is to determine if oxaloacetate (OAA) is safe and tolerable at
doses of up to 2 grams per day in people with Alzheimer's disease (AD).

The NeuroBlate® System (NBS) is a minimally invasive robotic laser thermotherapy tool that
is being manufactured by Monteris Medical. Since it received FDA clearance in April 2013,
the NBS has been used in over 300 procedures conducted at approximately 20 leading
institutions across United States. This is a prospective, multi-center registry that will
include data collection up to 12 months to evaluate procedural success, local control
failure rate, and QoL in up to 1,000 patients and up to 50 sites.

Pages